BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11840401)

  • 21. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.
    Erlichman C; Fine S; Wong A; Elhakim T
    J Clin Oncol; 1988 Mar; 6(3):469-75. PubMed ID: 3280741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
    Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
    Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Combined 5-FU and CDDP in a gastric cancer patient undergoing hemodialysis--pharmacokinetics of 5-FU and CDDP].
    Cho H; Imada T; Masudo K; Doi C; Inaba M; Tokunaga M; Takanashi Y
    Gan To Kagaku Ryoho; 2000 Nov; 27(13):2135-8. PubMed ID: 11103248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma. A phase I-II study of two consecutive regimens.
    Machover D; Grison X; Goldschmidt E; Zittoun J; Metzger G; Richaud J; Lotz JP; André T; Hannoun L; Marquet J
    Ann Oncol; 1993; 4 Suppl 2():29-35. PubMed ID: 8353102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.
    Scheithauer W; Kornek GV; Marczell A; Karner J; Salem G; Greiner R; Burger D; Stöger F; Ritschel J; Kovats E; Vischer HM; Schneeweiss B; Depisch D
    Br J Cancer; 1998 Apr; 77(8):1349-54. PubMed ID: 9579845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
    Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
    Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients.
    Coustère C; Mentré F; Sommadossi JP; Diasio RB; Steimer JL
    Cancer Chemother Pharmacol; 1991; 28(2):123-9. PubMed ID: 2060083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics.
    Presant CA; Wolf W; Albright MJ; Servis KL; Ring R; Atkinson D; Ong RL; Wiseman C; King M; Blayney D
    J Clin Oncol; 1990 Nov; 8(11):1868-73. PubMed ID: 2230874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid.
    Jansman FG; Coenen JL; De Graaf JC; Tobi H; Sleijfer DT; Brouwers JR
    Anticancer Res; 2002; 22(6B):3449-55. PubMed ID: 12552938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma.
    Grem JL; McAtee N; Balis F; Murphy R; Venzon D; Kramer B; Goldspiel B; Begley M; Allegra CJ
    Cancer; 1993 Aug; 72(3):663-8. PubMed ID: 8334622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
    Gamelin E; Delva R; Jacob J; Merrouche Y; Raoul JL; Pezet D; Dorval E; Piot G; Morel A; Boisdron-Celle M
    J Clin Oncol; 2008 May; 26(13):2099-105. PubMed ID: 18445839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.
    Arkenau HT; Rettig K; Porschen R
    Int J Colorectal Dis; 2005 May; 20(3):258-61. PubMed ID: 15549327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
    Harte RJ; Matthews JC; O'Reilly SM; Tilsley DW; Osman S; Brown G; Luthra SJ; Brady F; Jones T; Price PM
    J Clin Oncol; 1999 May; 17(5):1580-8. PubMed ID: 10334547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure.
    Gusella M; Rebeschini M; Cartei G; Ferrazzi E; Ferrari M; Padrini R
    Ther Drug Monit; 2005 Dec; 27(6):816-8. PubMed ID: 16306860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
    Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
    Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
    Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences.
    Boisdron-Celle M; Craipeau C; Brienza S; Delva R; Guérin-Meyer V; Cvitkovic E; Gamelin E
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):235-43. PubMed ID: 11935216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
    Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients.
    Casale F; Canaparo R; Serpe L; Muntoni E; Pepa CD; Costa M; Mairone L; Zara GP; Fornari G; Eandi M
    Pharmacol Res; 2004 Aug; 50(2):173-9. PubMed ID: 15177306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of advanced colonic and rectal adenocarcinoma: combination of 5-FU and high-dose folinic acid].
    Rougier P; Droz JP; Ducreux M; Kac J; Spielmann M; Crespon B; Ley G; Zimmermann P; Theodore C; Chavy A
    Bull Cancer; 1983; 70(5):434-6. PubMed ID: 6607759
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.